Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases

Table 2 Univariate and multivariate analysis for local control (LC)

Variables	HR	Univariate analysis		OR	Multivariate analysis
Variables	HR	IC95%	p	OR	IC95%	p
Histology (lung vs. others)	0.84	0.47–1.51	0.57
Age (≤55 vs. > 55)	1.94	2.06–3.58	0.01	0.98	0.95–1.01	0.11
Gender (male vs. female)	1.29	0.75–2.22	0.35
DS-GPA (> 2.5 vs. ≤2.5)	0.49	0.27–0.88	0.02	0.87	0.79–1.87	0.39
RPA (1 vs. > 1)	0.73	0.41–1.28	0.29
Number of BM (1 vs. > 1)	0.69	0.39–1.23	0.23
ECM (yes vs. No)	1.01	0.57–1.76	0.84
KPS (< 80% vs. ≥80%)	1.40	0.74–2.62	0.29
GTV volume (≥2.07 vs. < 2.07)	1.75	1.00–3.06	0.03	2.04	1.03–4.01	0.039
Size (> 10 mm vs. < 10 mm)	1.16	0.64–2.10	0.61
Dose distribution (HG vs. INH)	0.58	0.34–1.01	0.06
ST concurrently (group 1 vs. group 2)	0.73	0.42–1.28	0.32
IT (yes vs. no)	0.68	0.35–1.31	0.30
IT concurrently (yes vs. no IT)	0.33	0.16–0.66	0.02	0.18	0.12–0.79	0.022
TT (yes vs. no)	0.93	0.52–1.66	0.93
TT concurrently (yes vs. no TKI)	0.92	0.50–1.67	0.79
CT (yes vs. no)	1.22	0.71–2.09	0.46
CT concurrently (yes vs. no CT)	0.79	0.46–1.37	0.40
Prior WBRT (yes vs. no)	2.26	1.16–4.48	0.003	0.93	0.83–2.62	0.14

Abbreviations: DS-GPA Diagnostic-Specific Graded Prognostic Assessment, RPA Recursive partitioning analysis, BM Brain metastases, ECM Extracranial metastases, KPS Karnofsky Performance Status, GTV Gross Tumor Volume, HG Homogeneous, INH Inhomogeneous, ST Systemic Treatment, IT Immunotherapy, TT Targeted therapy, CT Chemotherapy, WBRT Whole brain radiotherapy

ISSN: 1471-2407